CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$4.24
-0.22 (-4.93%)
Open$4.37
Previous Close$4.46
Day High$4.42
Day Low$4.15
52W High$6.35
52W Low$0.40
Volume—
Avg Volume3.40M
Market Cap926.81M
P/E Ratio33.08
EPS$0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,386.8% upside
Current
$4.24
$4.24
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 275.61M | 178.16M | 145.29M |
| Net Income | 63.61M | 37.01M | 18.60M |
| Profit Margin | 23.1% | 21.9% | 12.8% |
| EBITDA | 53.04M | 32.57M | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +54.7% | +54.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |